Stifel on Disc Medicine (IRON): 'favor owning the stock on the basis of IRON’s programs in myelofibrosis and polycythemia vera'
Tweet Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $125.00 price target on Disc Medicine (NASDAQ: IRON).The analyst comments :Today ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
